Conduit Pharmaceuticals Stock Today
| CDT Stock | 0.11 0.01 11.00% |
Performance0 of 100
| Odds Of DistressLess than 32
|
Conduit Pharmaceuticals is selling for under 0.11 as of the 2nd of December 2024; that is 11.00% up since the beginning of the trading day. The stock's last reported lowest price was 0.0975. Conduit Pharmaceuticals has about a 32 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Equity ratings for Conduit Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 7th of January 2024 and ending today, the 2nd of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 25th of September 2023 | Category Healthcare | Classification Health Care |
Conduit Pharmaceuticals is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 116.8 M outstanding shares of which 2.36 M shares are currently shorted by investors with about 0.14 days to cover. More on Conduit Pharmaceuticals
Moving together with Conduit Stock
Moving against Conduit Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Conduit Stock Highlights
| CEO Director | David Tapolczay | |||||||||||||||||||||||||||||||||||||||||||||
| Old Name | Codeaddict S.A. | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Life Sciences Tools & Services, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Life Sciences Tools & Services, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
| Conduit Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Conduit Pharmaceuticals' financial leverage. It provides some insight into what part of Conduit Pharmaceuticals' total assets is financed by creditors. | ||||||||||||||||||||||||||||||||||||||||||||||
Conduit Pharmaceuticals (CDT) is traded on NASDAQ Exchange in USA. It is located in 4995 Murphy Canyon Road, San Diego, CA, United States, 92123 and employs 7 people. Conduit Pharmaceuticals is listed under Life Sciences Tools & Services category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a total capitalization of 12.46 M. Conduit Pharmaceuticals runs under Life Sciences Tools & Services sector within Health Care industry. The entity has 116.8 M outstanding shares of which 2.36 M shares are currently shorted by investors with about 0.14 days to cover.
Conduit Pharmaceuticals generates negative cash flow from operations
Check Conduit Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationConduit Pharmaceuticals holds a total of 116.8 Million outstanding shares. Conduit Pharmaceuticals retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Conduit Ownership Details
Conduit Pharmaceuticals Historical Income Statement
Conduit Stock Against Markets
Additional Tools for Conduit Stock Analysis
When running Conduit Pharmaceuticals' price analysis, check to measure Conduit Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Conduit Pharmaceuticals is operating at the current time. Most of Conduit Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Conduit Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Conduit Pharmaceuticals' price. Additionally, you may evaluate how the addition of Conduit Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.